On April 30, Dezhan Healthcare Company Limited(000813) ( Dezhan Healthcare Company Limited(000813) ) disclosed the announcement on the share repurchase plan of the company, saying that it plans to use its own funds to repurchase the company’s shares in the form of centralized bidding transaction. The repurchase price is no more than 5.40 yuan / share, and the total repurchase amount is no less than 178 million yuan and no more than 345 million yuan. The repurchased shares will be used to cancel and reduce the company’s registered capital, equity incentive plan or employee stock ownership plan. If the equity incentive plan is not implemented within 36 months after the completion of this repurchase, the shares repurchased will be cancelled according to law.
According to the announcement, according to the maximum repurchase price of 5.40 yuan / share and the total repurchase funds, the number of shares that can be repurchased is expected to be 33-64 million, accounting for about 1.48% – 2.87% of the total share capital of the company. Among them, the number of repurchased shares used to cancel and reduce the registered capital of the company shall not be less than 80% of the actual number of repurchased shares, and the number of repurchased shares used for equity incentive plan or employee stock ownership plan shall not be higher than 20% of the actual number of repurchased shares.
Dezhan Healthcare Company Limited(000813) said that the management of the company decided to buy back part of the company’s shares with its own funds and use the repurchased shares to cancel and reduce the company’s registered capital, equity incentive plan or employee stock ownership plan, so as to enhance investor confidence and stabilize investor expectations, Further establish and improve the company’s long-term incentive mechanism to effectively safeguard the interests of investors.
It is reported that Dezhan Healthcare Company Limited(000813) main product is in the industry of blood lipid regulator. The company has been rooted in China’s blood lipid regulating / reducing drug market for 20 years. Its main product “alo” is one of the prescription drugs with the largest sales in the world, and Lipitor is the first generic drug in China. The share of atorvastatin and simvastatin in the top ten medical institutions rose to about 45%, and the share of atorvastatin and simvastatin fell to about 5%. In June 2021, the company successfully obtained the drug registration certificate of two specifications of amlodipine atorvastatin calcium tablets. At present, the company is actively promoting the production and sales of the above drugs.
In addition, in recent years Dezhan Healthcare Company Limited(000813) actively promoted the diversified development mode and gradually distributed biological peptides and other fields. At present, the company’s product pipeline involves many industries such as influenza vaccine.
Looking back on the previous history, Xinjiang Kaidi investment received 7.49% of the equity of the listed company in 2021. After the completion of the transaction, Kaidi investment and its persons acting in concert held Dezhan Healthcare Company Limited(000813) 2382% of the equity, Dezhan Healthcare Company Limited(000813) controlling shareholder was changed to Kaidi investment, and the actual controller of the company was changed to Xinjiang SASAC.
At present, most of the listed companies controlled by Xinjiang SASAC are traditional industries, Dezhan Healthcare Company Limited(000813) is the first listed enterprise of medicine and health controlled by Xinjiang SASAC. . On the other hand, the company’s diversified industries such as biological peptides, vaccines, cosmetics and food and beverage are in the early layout. After Xinjiang state-owned assets take over, it is expected to provide strong support for Dezhan Healthcare Company Limited(000813) diversified business expansion from the market and capital levels and add new vitality to the company. (Qin Sheng)
